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Aim To identify predictors of 3-month mortality after heart trans-
plantation in a Croatian academic center.
Methods A retrospective review of institutional database identified 
117 heart transplantations from January 2008 to July 2014. Two chil-
dren <14 years were excluded from the study. The remaining 115 
patients were dichotomized into survivors and non-survivors adju-
dicated at 3-months postoperatively, and their demographic, clini-
cal, and longitudinal hemodynamic data were analyzed.
Results 3-month survival after heart transplantation was 86%. Non-
survivors were older (59 ± 8 vs 50 ± 14 years, P = 0.009), more likely 
to have previous cardiac surgery (44% vs 19%; odds ratio [OR] 3.28, 
95% confidence interval [CI] 1.08-9.90; P = 0.029), lower body mass 
index (BMI) (25 ± 4 vs 28 ± 2 kg/m2, P = 0.001), and be diabetics (44% 
vs 23%; OR 2.57, 95% CI 0.86-7.66; P = 0.083). Creatinine clearance 
was marginally superior among survivors (59 ± 19 vs 48 ± 20 mL/
min, P = 0.059). Donor age and sex did not affect outcomes. Non-
survivors were more likely to have had ischemic cardiomyopathy 
(69% vs 32%, P = 0.010). Postoperative utilization of epinephrine as a 
second line inotropic agent was a strong predictor of mortality (63% 
vs 7%; OR 21.91; 95% CI 6.15-78.06; P < 0.001). Serum lactate con-
centrations were consistently higher among non-survivors, with the 
difference being most pronounced 2 hours after cardiopulmonary 
bypass (9.8 ± 3.5 vs 5.2 ± 3.2 mmol/L, P < 0.001). The donor hearts 
exhibited inferior early hemodynamics in non-survivors (cardiac in-
dex 3.0 ± 1.0 vs 4.0 ± 1.1 L/min/m2, P = 0.001), stroke volume (49 ± 24 
vs 59 ± 19 mL, P = 0.063), and left and right ventricular stroke work 
indices (18 ± 8 vs 30 ± 11 g/beat/m2, P < 0.001 and 5 ± 3 vs 7 ± 4 g/
beat/m2, P = 0.060, respectively). Non-survivors were more likely to 
require postoperative re-sternotomy (50% vs 12%; OR 7.25, 95% CI 
2.29-22.92; P < 0.001), renal replacement therapy (RRT) (69% vs 9%; 
OR 22.00, 95% CI 6.24-77.54; P < 0.001), and mechanical circulatory 
assistance (MCS) (44% vs 5%; OR 14.62, 95% CI 3.84-55.62; P < 0.001). 
Binary logistic regression revealed recipient age (P = 0.024), serum 
lactates 2 hours after CPB (P = 0.007), and epinephrine use on post-
operative day 1 (P = 0.007) to be independently associated with 
3-month mortality.
Conclusion Pretransplant predictors of adverse outcome after 
heart transplantation were recipient age, lower BMI, ischemic car-
diomyopathy, reoperation and diabetes. Postoperative predictors 
of mortality were inferior donor heart hemodynamics, epinephrine 
use, and serum lactate concentrations. Non-survivors were more 
likely to require re-sternotomy, MCS, and RRT. 
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Heart failure (HF) presents a major public health burden, 
and its management consumes a large proportion of the 
health care budget (1,2). While the clinical syndrome of 
HF is multifactorial in origin, its cardinal symptoms are 
remarkably similar irrespective of the diverse underlying 
cardiac pathology. The adverse impact of HF on the qual-
ity of life and overall mortality has brought the issue into 
focus of the contemporary medical community. The al-
ready high financial burden of HF will likely increase in 
parallel to increasing age of the general population. Con-
trariwise, the number of orthotopic heart transplantation 
(OHT) worldwide has plateaued over the past decade (3). 
The unmatched need for donor organs has served as a 
strong impetus for the development of alternative lines 
of management, including mechanical circulatory as-
sistance. While we have witnessed both an accelerated 
evolution of ventricular assist devices and their wider dis-
semination within the HF population, the high incidenc-
es of associated complications reduce the effectiveness 
of this line of management. The contemporary armamen-
tarium for HF management also includes pharmaceutical 
modulation of multiple targets and biventricular pacing. 
This complex array of management tools notwithstand-
ing, OHT remains the unchallenged gold standard when 
it comes to long-term outcomes for patients with end-
stage HF (4). The importance of effective utilization of 
available organs is paramount in the setting of a pro-
nounced shortage of suitable allografts. The aim of this 
study was to identify the predictors of adverse 3-month 
outcome following heart transplantation in a tertiary-
care academic center.
MetHoDS
Study design
We conducted a retrospective chart review of all heart 
transplant recipients aged over 14 years, operated on at 
the University Hospital Center Zagreb, Croatia from Janu-
ary 1, 2008 to July 15, 2014. The local Institutional Review 
Board approved the study. Written informed consent was 
waived due to the retrospective nature of the study.
Data collection, variables examined, and outcome 
measure
During the observed study period 117 heart transplanta-
tions were performed and were screened for study en-
rollment. Of these, 2 were performed in children aged 
<14 years. These were excluded from further analy-
sis. After identifying cases from the institutional electron-
ic database, individual medical records were reviewed for 
demographic, clinical, history, laboratory and hemody-
namic data. Studied donor variables were donor age and 
sex. Comorbidities examined were diabetes, hypertension, 
hyperlipidemia, smoking, and atrial fibrillation. Pulmonary 
artery catheters (Argon Medical Devices, Singapore) were 
placed universally through the jugular vein. Their correct 
positioning was based on pressure tracings. Thermodilu-
tion hemodynamic data were obtained in triplicate and 
then averaged. Hemodynamic measurements includ-
ed cardiac index, stroke volume, stroke work indices for 
both ventricles, central venous and pulmonary capillary 
wedge pressures, as well as systemic and pulmonary vas-
cular resistances. Blood samples and hemodynamic data 
acquired 2 hours after CPB and on postoperative days 1 
and 7 were used. The primary outcome of the study was 
3-month mortality.
Allograft implantation procedure
Every effort was made to reduce the allograft ischemic 
time by frequent communications between the procure-
ment and implanting teams. Ideally, a donor ischemic time 
of less than 4 hours was aimed for. The University of Wis-
consin solution was used for myocardial protection and 
cold storage from 2008 to 2012. Custodiol solution was 
used for the same purpose during the latter two years of 
the study period. The preferred allograft implantation ap-
proach was the bicaval technique during tepid cardio-
pulmonary bypass (CPB). The left atrial and aortic anas-
tomoses were performed on a cross-clamped aorta. The 
remaining anastomoses were performed on CPB with the 
heart perfused. The donor heart rate, after weaning from 
CPB, was maintained between 100-120 beats per minute 
by a combination of positive chronotropic agents and atri-
al pacing. Isoproterenol was our preferred agent for this 
purpose. Inotropic support typically included dobutamine 
or milrinone, or a combination of these agents. Epineph-
rine was used only when further escalation of inotropic 
support was deemed warranted. Nitric oxide was not used 
routinely. Synthetic prostaglandin E1 was used selectively 
in patients with pulmonary hypertension or elevated pul-
monary vascular resistance. Norepinephrine was used to 
counteract low systemic vascular resistance. Any evidence 
of hypoperfusion would have prompted escalation of ino-
tropic support. In the event that pharmacological cardiac 
support alone was insufficient, a low threshold for institut-
ing mechanical circulatory assistance (MCS) was practiced. 
The first line MCS for this indication was extracorporeal 
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membrane oxygenation. Right ventricular assist devices 
were used in select cases.
Immunosuppressive protocol
We relied on antithymocyte globulin for the induction of 
immunosuppression. Our institutional protocol included 
a combination of cyclosporine A, mycophenolate mofetil, 
and steroids for maintenance of immunosuppression. In 
select cases tacrolimus was used instead of cyclosporine 
A. An attempt was made to wean steroids off, beginning 
no sooner than six months after OHT. Individual immuno-
suppression drug dosages were tailored based on trough 
levels. Right ventricular endomyocardial biopsies were 
performed every 7-14 days over the early postoperative 
period. Rejection was graded in line with the revised Inter-
national Society for Heart and Lung Transplantation clas-
sification (5).
Statistical analysis
The continuous data are presented as mean values with 
their standard deviations, or absolute numbers and per-
centages. Categorical variables are presented as absolute 
numbers and percentages. Missing data were addressed 
using multiple imputations based on the Markov-chain 
Monte Carlo procedure to generate 20 imputed data sets 
during 2500 iterations. The percentages of missing data for 
the studied variables varied between 0% and 26%. Over 
50% of the studied variables had less than 10% of missing 
data. Over 90% of studied variables had less than 25% of 
missing data. The number of imputation used in the study 
provided a relative efficiency of 0.987. Normality of distri-
bution was tested with the Shapiro-Wilk test. Mann-Whit-
ney U test was utilized for data with non-normal distribu-
tion, whereas t test was used for analyzing continuous data 
following a normal distribution.
Variables found to be significantly associated with adverse 
outcome on univariate analysis were included in a binary lo-
gistic regression model. These included serum lactate con-
centrations and hemodynamic data found to be associat-
ed with adverse outcomes on univariate analysis. Age and 
body mass index (BMI) completed the list of covariates fit 
into the regression model. Categorical variables were com-
pared with the χ2 test. Odds ratios were used as a measure 
of the association between specific comorbidities/clinical 
characteristics and 3-month mortality. The respective 95% 
confidence intervals (CI) were provided. A two-tailed P val-
ue <0.05 was considered to be statistically significant. The 
data were processed using the IBM SPSS Statistics software 
package (version 22.0; Somers, NY, USA).
ReSuLtS
Baseline patient characteristics
Of the total of 117 patients who underwent ortothopic 
heart transplantation at our center, 115 met the inclusion 
criteria and were included in this analysis. There was no dif-
ference in sex between patients who survived 3 months 
after OHT and those who did not (Table 1). Non-survivors 
were older (59 ± 8 vs 50 ± 14 years; P = 0.009). The incidence 
of diabetes mellitus was marginally higher among non-
survivors (44% vs 23%; OR 2.57, 95% CI 0.86-7.66; P = 0.083). 
The impact of lower creatinine clearance on 3-month mor-
tality was just below the predefined threshold of statisti-
cal significance (non-survivors: 48 ± 20 vs survivors: 59 ± 19 
tABLe 1. Patient demographic and clinical data*
3-month outcome
Preoperative descriptors non-survivors, n (%) survivors, n (%) odds ratio (95% CI) P
Male recipients 14 (88) 72 (73) 2.63 (0.56-12.32) 0.207
Male donors 11 (69) 69 (70) 0.957 (0.306-2.993) 0.939
Hyperlipidemia  4 (25) 31 (31) 0.73 (0.22-2.45) 0.611
Hypertension  7 (44) 34 (34) 1.49 (0.51-4.34) 0.466
Diabetes mellitus  7 (44) 23 (23) 2.57 (0.86-7.66) 0.083
Smoking history  3 (19) 10 (10) 2.05 (0.50-8.46) 0.311
Atrial fibrillation  8 (50) 30 (30) 2.30 (0.79-6.70) 0.120
Reoperation  7 (44) 19 (19) 3.28 (1.08-9.90) 0.029
Preoperative inotropic support (any)  6 (38) 36 (36) 1.05 (0.35-3.13) 0.930
Preoperative epinephrine  3 (19)  7 (7) 3.03 (0.70-13.22) 0.124
Preoperative MCS  5 (31) 17 (17) 2.19 (0.67-7.13) 0.184
*Abbreviations: CI – confidence intervals; MCS – mechanical circulatory assistance.
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mL/min; P = 0.059) (Table 2). Pulmonary vascular resistanc-
es (PVR) and N-terminal prohormone of brain natriuretic 
peptide values were not different between the groups (Ta-
ble 2). The primary cardiac pathology among survivors was 
dilatative cardiomyopathy (58% vs 31%; P = 0.061) (Table 3). 
Conversely, ischemic cardiomyopathy was more prevalent 
among non-survivors (69% vs 32%; P = 0.010). Of note, the 
preoperative use of MCS did not adversely affect the out-
come (Table 1).
3-month outcome
Three-month survival after OHT was 86% (99/115). The 
causes of death were sepsis (9 patients), RV failure (3 pa-
tients), stroke (1 patient), mesenteric ischemia (1 patient), 
and bleeding (2 patients). Non-survivors were never dis-
charged from the hospital. The donor ischemic times were 
similar between survivors and non-survivors (Table 2). A 
quarter of non-survivors and 17% of survivors had isch-
emic times that exceeded 4 hours (P = 0.452). Neither do-
nor sex nor donor age was predictive of 3-month mortal-
ity (Tables 1 and 2). The prevalence of donors older than 
50 years was similar between non-survivors and survivors 
(19% vs 17%; P = 0.877). Among the most robust predictors 
of adverse 3-month outcome were the serum lactate con-
centrations. Non-survivors had higher serum lactate con-
centrations over the early postoperative course (Figure 1). 
The predictive value of serum lactates on 3-month survival 
was highest for the values taken 2 hours after CPB (non-
survivors: 9.8 ± 3.5 vs survivors: 5.2±3.2 mmol/L; P < 0.001). 
Postoperative inotropic support was employed almost 
universally in the immediate post-procedural period, with-
out any difference between survivors and non-survivors. 
However, the use of epinephrine as an inotropic agent was 
linked to 3-month mortality (Table 4). Epinephrine use was 
limited to patients requiring a second line inotropic agent. 
Patients who required epinephrine on postoperative day 
1 were significantly more likely to die within 3 months of 
OHT (63% vs 7%; OR 21.91, 95% CI 6.15-78.06; P < 0.001). A 
similar trend was seen in patients in whom epinephrine 
was administered both immediately after CPB and as far 
into their postoperative course as day 7 post-OHT (Table 
4). Non-survivors were more likely to require at least one 
re-sternotomy for any reason (50% vs 12%; OR 7.25, 95% CI 
2.29-22.92; P < 0.001). Postoperative MCS was employed in 
patients in whom pharmacological augmentation of car-
diac function proved insufficient for maintaining optimal 
systemic perfusion. Clearly, this scenario was much more 
common among non-survivors (44% vs 5%; OR 14.62, 95% 
CI 3.84-55.62; P < 0.001). Non-survivors also required lon-
tABLe 2. Continuous descriptors of patient cohorts*
3-month outcome
non-survivors, mean (SD) survivors, mean (SD) P
Preoperative descriptors
Recipient age (years)   59 (8)   50 (14) 0.009
Donor age (years)   38 (13)   38 (12) 0.916
Body mass index (kg/m2)   25 (4)   28 (2) 0.001
Creatinine clearance (mL/min)   48 (20)   59 (19) 0.059
NT-proBNP 7559 (4380) 8009 (6738) 0.701
Preoperative lactate (mmol/L)    2.8 (1.4)    2.6 (2.4) 0.167
PVR  242 (122)  247 (137) 0.890
Peri-procedural descriptors
Ischemic time  193 (58)  178 (61) 0.355
CPB duration (min)  194 (70)  170 (72) 0.145
Mechanical ventilation (hrs)  266 (177)   46 (52) <0.001
*Abbreviations: SD – standard deviation; Nt-proBNP – N-terminal prohormone of brain natriuretic peptide; PVR – pulmonary vascular resistance; 
CPB – cardiopulmonary bypass.
tABLe 3. Primary cardiac pathology antedating heart trans-
plantation*
3-month outcome
non-survivors, 
n (%)
survivors, 
n (%) P
Dilatative CMP  5 (31) 57 (58) 0.061
Ischemic CMP 11 (69) 32 (32) 0.010
Valvular CMP  0 (0)  2 (2) 1.0
Restrictive CMP  0 (0)  2 (2) 1.0
Hypertrophic obstructive CMP  0 (0)  2 (2) 1.0
Grown-up congenital disease  0 (0)  2 (2) 1.0
ARVD  0 (0)  2 (2) 1.0
*Abbreviations: CMP – cardiomyopathy; ARVD – arrhythmogenic right 
ventricular dysplasia.
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tABLe 4. Postprocedural patient characteristics*
3-month outcome
non-survivors, n (%) survivors, n (%) odds ratio (95% CI) P
Postoperative cardiac support
Any inotrope T1 15 (94) 91 (92)  1.32 (0.15-11.31) 0.800
Epinephrine T1  6 (38) 11 (11)  4.80 (1.46-15.79) 0.006
Any inotrope T2 16 (100) 84 (85)  1.19 (1.09-1.30)† 0.095
Epinephrine T2 10 (63)  7 (7) 21.91 (6.15-78.06) <0.001
Any inotrope T3 11 (85) 62 (63)  3.28 (0.69-15.63) 0.118
Epinephrine T3  7 (54) 19 (19)  4.91 (1.48-16.30) 0.005
Postoperative MCS  7 (44)  5 (5) 14.62 (3.84-55.62) <0.001
Postoperative complications
RRT 11 (69)  9 (9) 22.00 (6.24-77.54) <0.001
CVI  2 (13)  4 (4)  3.39 (0.57-20.28) 0.158
Re-sternotomy  8 (50) 12 (12)  7.25 (2.29-22.92) <0.001
*Abbreviations: CI – confidence intervals; t1 – 2 hours post CPB; t2 – postoperative day 1; t3 – postoperative day 7; MCS – mechanical circulatory 
support; RRt – renal replacement therapy; CVI – cerebrovascular incident.
†Relative risk.
FIGuRe 1. Box and whisker plots showing the serum lactate concentrations in survivors and non-survivors over the early postopera-
tive period. Boxes represent the 25th and 75th percentiles, and horizontal lines within the boxes are the median values. the whiskers 
illustrate the minimum and maximum values.
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ger periods of mechanical ventilation (266 ± 177 vs 46 ± 52 
hours; P < 0.001).
Hemodynamic data
Preoperative hemodynamics of the recipient’s native hearts 
did not affect 3-month postoperative outcome (Table 5). 
Contrariwise, the hemodynamic performance of the trans-
planted donor heart had a significant effect on 3-month 
mortality (Table 5, Figure 2). Cardiac index (CI) and stroke 
volume (SV) 2 hours after CPB were lower in non-survi-
vors (3.0 ± 1.0 vs 4.0 ± 1.1 L/min/m2; P = 0.001 and 49 ± 24 
vs 59 ± 19 mL; P = 0.063, respectively). Left and right ven-
tricular stroke work indices calculated simultaneously with 
the aforementioned hemodynamic parameters were also 
lower in non-survivors (left ventricular stroke work index 
[LVSWI]: 18 ± 8 vs 30 ± 11 g/beat/m2; P < 0.001; right ven-
tricular stroke work index [RVSWI]) 5 ± 3 vs 7 ± 4 g/beat/m2; 
P = 0.060). Similar trends were observed for thermodilution 
hemodynamic data on postoperative day 1 with the nota-
ble exception of RVSWI, which was no longer predictive of 
poor outcome (Table 5). Three patients died prior to post-
operative day 7, negating the effect their hemodynamics 
would have had on the data acquired at that time.
Binary logistic regression
Variables found to be significantly associated with adverse 
3-month outcome on univariate analysis were included 
in a binary logistic regression model. Logistic regression 
revealed recipient age (P = 0.024), serum lactates 2 hours 
after CPB (P = 0.007), and epinephrine use on postopera-
tive day 1 (P = 0.007) to be independently associated with 
3-month mortality.
FIGuRe 2. Box and whisker plots depicting the thermodilution-derived cardiac index in survivors and non-survivors over the early 
postoperative period. Boxes represent the 25th and 75th percentiles, and horizontal lines within the boxes are the median values. 
the whiskers illustrate the minimum and maximum values.
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DISCuSSIoN
Heart transplantation remains the best therapeutic option 
for patients with end-stage heart failure (4). The scarcity 
of available donor organs mandates constant refinement 
of selection algorithms designed to improve long-term 
results of OHT. Our study aimed to identify pretransplant 
and perioperative predictors of adverse 3-month out-
come in a Croatian academic center. It showed that older 
recipient age was a significant contributor to poor out-
come after OHT, similar to previous publications on the 
subject (6). We rarely accepted marginal donors in our 
practice, which may explain why donor age was not pre-
dictive of poor outcome. Donor age >50 years has been 
shown to be a predictor of allograft non-utilization (7). In 
our study, the proportion of donors aged >50 years was 
tABLe 5. Longitudinal analysis of hemodynamic descriptors*
3-month outcome
non-survivors, mean (SD) survivors, mean (SD) P
Preoperative data (prior to skin incision)
Cardiac index (L/min/m2)    1.9 (0.6)    2.0 (0.7) 0.698
Stroke volume (mL)   51 (18)   48 (19) 0.495
LVSWI (g/beat/m2)   17 (7)   20 (9) 0.322
RVSWI (g/beat/m2)    6 (3)    6 (3) 0.723
PVR (dyn · s · cm−5)  242 (122)  247 (137) 0.814
SVR (dyn · s · cm−5) 1287 (470) 1384 (484) 0.479
CVP (mm Hg)   19 (7)   16 (6) 0.190
PCWP (mm Hg)   26 (8)   23 (8) 0.254
2-hrs post CPB
Cardiac index (L/min/m2)    3.0 (1.0)    4.0 (1.1) 0.001
Stroke volume (mL)   49 (24)   59 (19) 0.063
LVSWI (g/beat/m2)   18 (8)   30 (11) <0.001
RVSWI (g/beat/m2)    5 (3)    7 (4) 0.060
PVR (dyn · s · cm−5)  148 (56)  125 (51) 0.162
SVR (dyn · s · cm−5)  840 (278)  723 (257) 0.058
CVP (mm Hg)   16 (6)   15 (5) 0.543
PCWP (mm Hg)   17 (5)   17 (5) 0.625
PoD 1
Cardiac index (L/min/m2)    3.3 (0.9)    3.8 (0.8) 0.075
Stroke volume (mL)   57 (23)   65 (18) 0.132
LVSWI (g/beat/m2)   25 (9)   33 (10) 0.007
RVSWI (g/beat/m2)    5 (2)    5 (2) 0.702
PVR (dyn · s · cm−5)  112 (44)  104 (52) 0.461
SVR (dyn · s · cm−5)  779 (213)  830 (299) 0.794
CVP (mm Hg)   15 (4)   15 (4) 0.762
PCWP (mm Hg)   16 (3)   16 (4) 0.606
PoD 7
Cardiac index (L/min/m2)    3.9 (0.8)    3.4 (0.7) 0.069
Stroke volume (mL)   62 (18)   63 (19) 0.848
LVSWI (g/beat/m2)   33 (13)   37 (19) 0.353
RVSWI (g/beat/m2)    7 (3)    5 (2) 0.085
PVR (dyn · s · cm−5)  121 (34)  119 (44) 0.558
SVR (dyn · s · cm−5)  849 (275)  990 (279) 0.100
CVP (mm Hg)   13 (4)   14 (5) 0.439
PCWP (mm Hg)   15 (4)   15 (4) 0.948
*Abbreviations: SD – standard deviation; LVSWI – left ventricular stroke work index; RVSWI – right ventricular stroke work index; PoD – postopera-
tive day; PVR – pulmonary vascular resistance; SVR – systemic vascular resistance; CVP – central venous pressure; PCWP – pulmonary capillary 
wedge pressure; CPB – cardiopulmonary bypass.
ADVANCED HEART FAILURE560 Croat Med J. 2014;55:553-61
www.cmj.hr
not different between the two cohorts. Similarly, dura-
tion of myocardial ischemia was not different between 
survivors and non-survivors. Croatia is a member of the 
Eurotransplant framework and organs frequently arrive 
from other countries. Even with international organ trans-
port, we were able to limit our ischemic times to less than 
4 hours in over 80% of transplantations.
In our trial, diabetic patients had marginally inferior out-
comes. This point may prove to be even more important 
in the future, as we are already witnessing the inclusion of 
increasingly more complex patients into heart transplanta-
tion programs (8). Our data on post-transplantation out-
come in diabetics support previous publications investi-
gating predictors of mortality (9,10). Our trial also showed 
the impact of prior sternotomy on worse survival, which 
is in accordance with earlier data (9). The predictive ca-
pacity of inferior creatinine clearance has been illustrated 
earlier (9). In our study, the impact of worse renal function 
on mortality was rather close to the level of statistical sig-
nificance. The impact of recipient and donor sex on post-
operative outcomes has been a point of controversy, as 
has been the importance of sex-specific donor-recipient 
matching (9,11). Our study did not support any inferior sex-
specific outcomes, but was not powered to investigate the 
potentially important male to female mismatches among 
donors and recipients.
Serum lactate concentrations are robust markers of hy-
poperfusion. In our study, lactate levels 2-hours after com-
pletion of the procedure proved to be excellent indicators 
of early post-transplant survival. Maintaining optimal sys-
temic and regional perfusion is of critical importance in the 
immediate postoperative setting. Our study underscores 
the fact that even temporary hypoperfusion in the early 
post-transplantation period may have long-term conse-
quences on patient outcomes. The importance of the early 
functional performance of the transplanted heart is fur-
ther corroborated by the increase in 3-month mortality in 
patients with inferior thermodilution-based perioperative 
hemodynamic measurements. Optimization of hemody-
namics may rely on both pharmacological and mechani-
cal circulatory assistance. The requirement for epinephrine 
in our practice was an ominous patient characteristic. Epi-
nephrine use in our setting was a surrogate of the severity 
of underlying hemodynamic compromise, and its associa-
tion with poor outcome may reflect more on the patient 
condition than on drug-specific attributes. Analogously, 
the use of postoperative MCS was limited to patients 
with the most pronounced reduction of cardiac per-
formance, and hence associated with 3-month mortality. 
Optimizing MCS timing is pivotal for maintaining good 
postoperative results. Our study showed that there were 
patients in whom early institution of mechanical circula-
tory assistance might be preferable over futile escalation 
of inotropic support.
Despite the clear shortage of available organs there is con-
tinued low utilization of available allografts (7). We were 
unable to identify any donor-specific criteria that led to 
inferior outcomes. Currently available evidence supports 
more liberal use of available allografts, the need for which 
is accentuated by the increasing number of patients suffer-
ing from end-stage heart failure (4).
Our study is a retrospective, single center analysis and 
therefore is burdened with limitations inherent to this 
study design. Furthermore, data harvested from institu-
tional databases and medical records relied on the accura-
cy and comprehensiveness of data input. Some of the ex-
amined variables had missing data, which was addressed 
with multiple imputation methodology. It is possible that 
some confounding variables were not included in the 
analysis due to their absence in the available medical re-
cords. In addition, our study was not powered to investi-
gate the impact of various sex-matched combinations be-
tween donors and recipients (such as male donor/female 
recipient, female donor/male recipient, sex-matched do-
nor/recipient).
In conclusion, the obtained results after OHT in a tertiary 
academic center in Croatia showed that recipient age, low-
er BMI, ischemic cardiomyopathy, reoperation and possibly 
diabetes and inferior creatinine clearance were pretrans-
plant predictors of 3-month mortality. Epinephrine use, se-
rum lactate concentrations, and re-sternotomy indicated a 
higher likelihood for an adverse outcome. Conversely, high 
cardiac output immediately after heart transplantation ex-
erted a favorable effect on 3-month survival. These results 
highlight the importance of optimizing donor heart per-
formance in the critical post-transplant period.
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